证券代码：688217 证券简称：睿昂基因 公告编号：2023-066 上海睿昂基因科技股份有限公司 股东减持计划时间届满未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 本次减持计划实施前，上海睿昂基因科技股份有限公司（以下简称"公司"） 股东苏州辰知德投资合伙企业（有限合伙）(以下简称"辰知德投资")持有公司股 份 1,291,997 股，占公司当时总股本的 2.32%。辰知德投资和杭州辰德投资合伙 企业（有限合伙）(以下简称"辰德投资")、上海辰贺投资中心（有限合伙）(以下 简称"辰贺投资")三者构成一致行动人关系，本次减持计划实施前合计持有公司 股份 2,908,561 股，占公司当时总股本的 5.23%。上述股份均为公司首次公开发 行前取得的股份，并于 2022 年 5 月 17 日起上市流通。 减持计划的实施结果情况 公司于 2023 年 2 月 4 日在上海证券交易所网站（www.sse.com.cn）披露的 《上海睿昂基因科技股份有限公司股东减持股份计划公告》（公告编号：20 ...

上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会的 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2023 年第四次临时股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《上市公司股东大会规则》等法律、法规和其他规范性文件以 及《上海睿昂基因科技股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所 ...

上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会会议资料 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会 会议资料 2023 年 8 月 上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会会议资料 | | | | 2023 | 年第四次临时股东大会会议须知 3 | | --- | --- | | 2023 | 年第四次临时股东大会会议议程 5 | | 2023 | 年第四次临时股东大会会议议案 7 | | | 议案一《关于补选公司第二届董事会独立董事的议案》 7 | 上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会会议资料 上海睿昂基因科技股份有限公司 2023 年第四次临时股东大会会议须知 为维护广大投资者的合法权益，确保上海睿昂基因科技股份有限公司（以下 简称"公司"或"睿昂基因"）股东大会的正常秩序和议事效率，保障股东在本 次股东大会期间依法行使权利，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、中国证监会《上市公司股东大会规则》和公司《股东大会议事规则》 等有关规定，特制定本会议须知： 一、公司负责 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688217 证券简称：睿昂基因 公告编号：2023-064 上海睿昂基因科技股份有限公司 关于召开 2023 年第四次临时股东大会的通知 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第四次临时股东大会 召开日期时间：2023 年 8 月 24 日 14 点 30 分 召开地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 24 日 至 2023 年 8 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 累积投票议案 | | | | 1.00 | 《关于补选公司第二届董事会独立董事的议 | 应选 ...

二、本人任职资格符合下列法律、行政法规和部门规章的要求: (一)《公司法》关于董事任职资格的规定; (二)《公务员法》关于公务员兼任职务的规定; (三)中央纪委、中央组织部《关于规范中管干部辞去公职或者 退(离)休后担任上市公司、基金管理公司独立董事、独立监事的通 知》的规定; (四)中央纪委、教育部、监察部《关于加强高等学校反腐倡廉 建设的意见》关于高校领导班子成员兼任职务的规定; 独立董事候选人声明 本人姜广策,已充分了解并同意由提名人上海睿昂基因科技股份 有限公司第二届董事会提名为上海睿昂基因科技股份有限公司第二 届董事会独立董事候选人。本人公开声明,本人具备独立董事任职资 格,保证不存在任何影响本人担任上海睿昂基因科技股份有限公司独 立董事独立性的关系,具体声明如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法 规、部门规章及其他规范性文件,具有五年以上法律、经济、财务、 管理或者其他履行独立董事职责所必需的工作经验,并已根据《上市 公司高级管理人员培训工作指引》及相关规定取得独立董事资格证书。 本人尚未取得上海证券交易所科创板独立董事培训记录证明,本人承 诺在本次提名后,将参加上海证券 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2023-065 上海睿昂基因科技股份有限公司 关于公司独立董事辞职及补选独立董事的公告 公司独立董事候选人姜广策先生已取得独立董事资格证书，尚未参加上海 证券交易所科创板独立董事网络课程培训，作为第二届董事会独立董事候选人 其已承诺将参加上海证券交易所最近一期科创板独立董事培训，并取得科创板 独立董事培训记录证明。 三、独立董事的独立意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、关于独立董事辞职的情况说明 上海睿昂基因科技股份有限公司（以下简称"公司"）董事会于近日收到独 立董事徐伟建先生提交的辞职报告，独立董事徐伟建先生因个人原因，申请辞 去公司第二届董事会董事及第二届董事会审计委员会委员、薪酬与考核委员会 委员、提名委员会委员的职务，辞职后，徐伟建先生不再担任公司任何职务。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海睿昂基 因科技股份有限公司章程》（以下简称"《公司章程》"）等相关规定，徐伟建 先生的辞职将导致公司独立董事人数少于董事 ...

我们认为：经过对公司第二届董事会独立董事候选人姜广策先生的背景、工 作经历的了解，我们认为该独立董事候选人的任职资格符合相关法律、行政法规、 规范性文件对独立董事任职资格的要求，不存在《公司法》《公司章程》《上市 公司独立董事规则》等相关法律、法规规定的不得担任公司独立董事的情形，该 名独立董事候选人未受到中国证券监督管理委员会的行政处罚或交易所惩戒，不 存在上海证券交易所认定不适合担任上市公司独立董事的其他情形。此外，独立 董事候选人姜广策先生已取得独立董事资格证书，其教育背景、工作经历均能够 胜任独立董事的职责要求。 综上，独立董事一致同意提名姜广策先生为公司第二届董事会独立董事候选 人，并同意将该事项提交公司2023年第四次临时股东大会审议。 上海睿昂基因科技股份有限公司 独立董事：袁学伟、徐伟建、赵贵英 2023年8月8日 上海睿昂基因科技股份有限公司 独立董事关于第二届董事会第十七次会议 相关事项的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证 券交易所科创板股票上市规则》《上市公司独立董事规则》等法律、行政法规、 部门规章和规范性文件，以及《上海睿昂基因科技股份有限公司 ...

独立董事提名人声明 提名人上海睿昂基因科技股份有限公司董事会,现提名姜广策为 上海睿昂基因科技股份有限公司第二届董事会独立董事候选人,并已 充分了解被提名人职业专长、教育背景、工作经历、兼任职务等情况。 被提名人已书面同意出任上海睿昂基因科技股份有限公司第二届董 事会独立董事候选人(参见该独立董事候选人声明)。提名人认为, 被提名人具备独立董事任职资格,与上海睿昂基因科技股份有限公司 之间不存在任何影响其独立性的关系,具体声明如下; 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、规章及其他规范性文件,具有五年以上法律、经济、财务、 管理或者其他履行独立董事职责所必需的工作经验,并已根据《上市 公司高级管理人员培训工作指引》及相关规定取得独立董事资格证书。 被提名人尚未取得上海证券交易所科创板独立董事培训记录证明,被 提名人已承诺在本次提名后,将参加上海证券交易所最近一期科创板 独立董事培训,并取得科创板独立董事培训记录证明。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求: (一)《公司法》关于董事任职资格的规定; (二)直接或间接持有上市公司已发行股份 1%以上或者是上市 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥56,884,419.55, representing a year-on-year increase of 17.84%[5] - Total revenue for Q1 2023 was ¥56,884,419.55, an increase of 18% compared to ¥48,273,660.16 in Q1 2022[17] - The net profit attributable to shareholders was ¥1,290,913.02, with a significant increase in sales volume compared to the same period last year[9] - Net profit for Q1 2023 was a loss of ¥5,300,038.19, slightly improved from a loss of ¥5,603,144.65 in Q1 2022[19] - Operating profit for Q1 2023 was a loss of ¥2,681,130.86, compared to a loss of ¥6,386,287.06 in Q1 2022, indicating a reduction in losses[18] - The company reported a total comprehensive loss of ¥5,300,038.19 for Q1 2023, compared to a loss of ¥5,603,144.65 in Q1 2022[19] Cash Flow - The net cash flow from operating activities reached ¥36,611,099.54, an increase of 1,153.46% year-on-year due to higher cash receipts from sales[6] - Cash inflow from operating activities in Q1 2023 was ¥119,526,990.15, significantly higher than ¥56,692,989.99 in Q1 2022, marking a 111% increase[19] - The net cash flow from operating activities for Q1 2023 was $36,611,099.54, a significant increase from $2,920,801.28 in Q1 2022, representing a growth of approximately 1,150%[20] - The total cash flow for the quarter resulted in a net decrease of $33,759,015.64, contrasting with an increase of $8,826,862.90 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,063,819,121.00, a decrease of 1.76% from the end of the previous year[6] - The company's current assets totaled ¥580,238,253.67, down from ¥624,479,327.42, indicating a decrease of about 7.1%[14] - Total liabilities decreased to ¥97,697,195.22 in Q1 2023 from ¥111,500,983.32 in Q1 2022, a reduction of approximately 12.4%[17] - The company reported a total of ¥42,839,952.35 in accounts payable, down from ¥51,180,535.03, indicating a decrease of approximately 16.5%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,363[11] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, accounting for 18.31% of the total shares[11] - Shareholders' equity attributable to the parent company increased to ¥938,186,855.60 in Q1 2023 from ¥936,895,942.58 in Q1 2022[17] Research and Development - Research and development expenses totaled ¥14,436,134.44, which is a decrease of 27.65% compared to the previous year, accounting for 25.38% of operating revenue, down by 15.95 percentage points[6] - Research and development expenses for Q1 2023 were ¥14,436,134.44, down from ¥19,953,750.23 in Q1 2022, a decrease of 27.5%[17] - The company has not provided any new product or technology development updates in the current report[13] Government Subsidies - The company received government subsidies amounting to ¥312,735.06, which are closely related to its normal business operations[7] Market and Future Outlook - There are no significant market expansion or acquisition strategies mentioned in the report[13] - The company has not issued any future performance guidance or outlook for the upcoming quarters[13] Accounting and Reporting - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[21]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[17]. - The company's operating revenue for 2022 was CNY 424,298,139.43, representing a year-on-year increase of 45.83% compared to CNY 290,951,595.17 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 40,473,558.80, a decrease of 14.49% from CNY 47,332,599.14 in 2021[24]. - The basic earnings per share for 2022 was CNY 0.73, down 23.16% from CNY 0.95 in 2021[25]. - The company achieved a revenue of 424.30 million yuan in 2022, representing a year-on-year growth of 45.83%[35]. - The net profit attributable to the parent company was 40.47 million yuan, a decrease of 14.49% compared to the previous year[35]. - The company reported a significant increase in testing business revenue, contributing to the overall rise in operating income[25]. - The company experienced a net loss of CNY 2,331,194.58 in the first quarter of 2022, followed by a profit of CNY 23,613,993.54 in the second quarter[26]. Research and Development - The company has not achieved profitability since its listing, indicating ongoing investment in research and development[7]. - The company emphasizes significant funding needs for R&D projects, fixed asset investments, and marketing network upgrades[6]. - Research and development expenses accounted for 15.18% of operating revenue in 2022, a decrease of 8.41 percentage points from 23.59% in 2021[25]. - The company invested 64.43 million yuan in R&D in 2022, accounting for 15.18% of the total revenue[37]. - The company has developed 3 core front-end technologies, 6 advanced molecular diagnostic application technologies, and 2 forward-looking reserve technologies in the field of molecular diagnostics[91]. - The company has obtained 55 patent authorizations, including 46 invention patents, 8 utility model patents, and 1 design patent, with 30 new patent applications filed during the year[95]. - The company has developed a multi-factor artificial intelligence algorithm for accurate prognosis assessment models for specific cancer patients[92]. - The company has launched a rapid FISH technology that reduces the traditional hybridization process time from 16-24 hours to just 1-2 hours[93]. Market Strategy and Expansion - The company is focused on expanding its market presence and developing new products and technologies[6]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[17]. - The company is actively collaborating with AstraZeneca and Merck in the field of precision diagnostics, enhancing its market presence and technological capabilities[69]. - The company aims to enhance its market presence through the promotion of its lymphoma gene rearrangement product, which has been recommended in national diagnostic guidelines[65]. - The company has established partnerships with three major hospitals to enhance its testing capabilities and expand its service offerings[17]. - The company has developed a direct sales marketing network covering over 300 top-tier hospitals nationwide[32]. - The company plans to increase market share in the follow-up and existing patient markets by enhancing initial patient conversion rates through a physician-patient software platform[191]. Risks and Challenges - The company has disclosed potential risks in its management discussion and analysis section, urging investors to be cautious[4]. - The company is facing risks related to new product development, registration, and technology iteration, which could impact its competitive advantage[112][115][116]. - The company is exposed to market competition risks due to the influx of new entrants and larger firms in the in vitro diagnostics market[119]. - The company is facing risks related to the renewal of medical device licenses, which could impact normal operations if not managed properly[121]. Operational Highlights - The company has established an automated laboratory capable of handling up to 20,000 tests per day, with AI cloud platform integration allowing for rapid report generation within 10 minutes[49]. - The company has accumulated a database of over 200,000 blood cancer detection data annually, enhancing its capabilities in clinical relevance analysis and data modeling[49]. - The company has a workforce of 503 employees, with over 57% holding a bachelor's degree or higher[32]. - The company has a total of 80 R&D personnel, accounting for 15.90% of the total workforce, with an average salary of CNY 18.96 million[104]. Product Development and Innovation - The company has developed a high-quality sales team and established a market strategy center to enhance its marketing system and support sales operations[46]. - The company is committed to the national strategy of "precision medicine," focusing on providing accurate genetic testing for cancer patients[50]. - The company has developed 36 antigen detection reagents in the immunodiagnostic field, achieving first-class registration for these products[94]. - The company has developed a unique database for primer-probe design technology, enhancing the specificity and efficiency of molecular diagnostics[92]. - The company is in the clinical trial phase for multiple new products, including the BCR-ABL fusion gene quantitative detection kit and JAK2 mutation detection kit[159]. Financial Position and Cash Flow - The net cash flow from operating activities for 2022 was CNY 73,068,987.33, a decrease of 6.28% from CNY 77,966,980.44 in 2021[24]. - Cash and cash equivalents increased by 65.25% to ¥203,850,876.14, up from ¥123,356,044.84 in the previous year[149]. - Trade receivables rose by 56.26% to ¥255,816,952.93, compared to ¥163,711,813.43 in the previous year, reflecting increased revenue scale[149]. - The company’s long-term assets under construction increased by 97.38% to ¥115,681,731.45, up from ¥58,609,551.51 in the previous year due to payments for new factory projects[149]. Regulatory and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[8]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has successfully registered multiple medical devices, enhancing its product portfolio and market presence[161].